CalmWave Named to Inc.'s 2025 Best Workplaces List

SEATTLE--(BUSINESS WIRE)-- CalmWave, creator of the Calm ICU™ and leader in eliminating non-actionable alarms through healthcare data science and Transparent AI, announced today that has been named to Inc.'s 2025 Best Workplaces list honoring companies that have built exceptional workplaces that support their teams and businesses.
'This recognition reflects the integrity, grit, and heart of our team and reinforces our belief that meaningful innovation begins with creating an exceptional place to work,' said Ophir Ronen, founder and CEO, CalmWave. 'We share a singular mission to transform healthcare by redefining and optimizing hospital operations, enabling clinicians to focus on what matters most: patient care. The entire CalmWave team is driven to make an impact, united by a shared commitment to improve healthcare for both clinicians and patients.'
CalmWave is the first effective solution to address the endemic problem of alarm fatigue in Intensive Care Units (ICUs). Alarm fatigue occurs when the constant stream of alarms overwhelms both clinicians and patients, often due to a flood of non-actionable alarms – alerts triggered by monitoring systems that do not require immediate intervention or clinical response. These alarms account for 80–99% of those in ICUs and are the primary cause of alarm fatigue. This cacophony not only increases the risk of negative outcomes such as ICU delirium but also places significant strain on healthcare staff, ultimately impacting overall patient care.
CalmWave is redefining hospital operations, starting by eliminating alarm fatigue in ICUs and expanding to deliver enterprise-wide operational intelligence that enhances clinical workflows, optimizes clinical engineering, and supports system-wide staff well-being. The Calm ICU™ is a signal-led critical care environment powered by CalmWave that reduces alarm burden using data science and allows clinical teams to focus on patient care, accelerate ICU throughput, improve patient safety and enhance hospital operations. It enables hospitals to align teams, technology, and time – informing decisions where they matter most: at the bedside.
'Inc.'s Best Workplaces program celebrates the exceptional organizations whose workplace cultures address their employees' welfare and needs in meaningful ways,' says Bonny Ghosh, editorial director at Inc. 'As companies expand and adapt to changing economic forces, maintaining such a culture is no small feat. Yet these honorees have not only achieved it – they continue to elevate the employee experience through thoughtful benefits, engagement, and a deep commitment to their teams.'
This year's list, featured on Inc.com, is the result of comprehensive measurement and evaluation of American companies that have excelled in creating exceptional workplaces and company cultures, whether in-person or remote.
The Best Workplaces award process involved a detailed employee survey conducted by Quantum Workplace covering critical occupational elements such as management effectiveness, perks, professional development, and overall culture. Company benefits were also audited to determine overall score and ranking. CalmWave is honored to be included among the 514 companies recognized this year.
To view the full list of winners, visit Inc.com.
About CalmWave
CalmWave's mission is to objectively improve healthcare, starting with safely eliminating non-actionable alarms. Alarms triggered by bedside monitoring systems that do not require immediate intervention or clinical response comprise 80-99% of all audible alarms in intensive care units (ICUs). They contribute to a well-recognized and widespread issue known as alarm fatigue, endemic to every hospital worldwide. Alarm fatigue, rampant in the modern healthcare system, causes great stress for clinicians and patients, ultimately impacting patient outcomes and staff retention. Using Transparent AI, CalmWave outlines the rationale behind each optimized setting, empowering a hospital's clinical staff to evaluate and implement optimized alarm limit recommendations in the bedside monitor at the patient's bedside using the CalmWave Operations Platform, which integrates seamlessly with the hospital's EMR. Doing so remediates alarm fatigue and can improve staff retention and patient outcomes. Visit CalmWave.ai for more information and follow us on LinkedIn and X.
About Inc.
Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit www.inc.com.
About Quantum Workplace
Quantum Workplace, based in Omaha, Nebraska, is an HR technology company that serves organizations through employee-engagement surveys, action-planning tools, exit surveys, peer-to-peer recognition, performance evaluations, goal tracking, and leadership assessment. For more information, visit QuantumWorkplace.com.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

33 minutes ago

• Business Wire

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. ( (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be participating in the call. Please connect to the call using the following link: The event and accompanying slides can also be accessed by visiting the investor relations section of the company's website at An archived webcast will be available on the company's website following the event. The FB102-101 Phase 1b celiac disease study enrolled 32 subjects 3:1 randomized (24 on FB102 and 8 on placebo). Subjects received 4 doses of FB102 (10 mg/kg) and underwent a 16 day gluten challenge. In addition to safety and tolerability, the study assessed morphologic and inflammatory endpoints along with gluten challenge (GC) induced symptoms. FB102 demonstrated a statistically significant benefit on the composite histological VCIEL endpoint (change from baseline). The mean VCIEL change from baseline was -1.849 for placebo subjects compared to 0.079 for FB102 treated subjects (p=0.0099). The change in the density of CD3-positive T cells, or IELs, from baseline was an increase of 13.3 for placebo subjects compared to a decline of 1.5 for FB102 treated subjects (p=0.0035). Baseline IEL density was 25.6 for the placebo subjects and 23.5 for the FB102 treated subjects. The mean change in the Vh:Cd ratio from baseline was -0.173 (0.21) for placebo subjects compared to -0.046 (0.09), a 73% improvement for FB102 treated subjects compared to placebo. Gluten challenge induced GI symptoms (nausea, vomiting, diarrhea, abdominal pain and abdominal bloating) reported during the 16 day gluten challenge from patient diaries/AE collection demonstrated a 42% benefit for FB102 treated subject (4.0 events per subject) compared to placebo (6.9 events per subject). There were no dropouts in the study. Treatment emergent adverse events (TEAE) were primarily mild (grade 1) with no grade 3 or higher SAEs reported in the FB102 arm. 'We want to congratulate all of the investigators and researchers that supported this study. I also want to acknowledge the incredible dedication and hard work of the Forte team. Celiac disease is debilitating for many patients with even trace exposure to gluten. FB102 has taken a big step forward towards addressing this very large unmet need with the results from this study. The Phase 2 celiac disease study is initiating with a topline readout expected in 2026.' said Paul Wagner, Ph.D. CEO and Chairperson of Forte Biosciences. 'These results are also very encouraging given the biology of the additional FB102 indications including vitiligo, alopecia areata and type 1 diabetes. We also look forward to reading out the topline results of the FB102 vitiligo study in the first half of 2026.' About Forte Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. Forward-Looking Statements Forte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential' or 'continue' or the negatives of these terms or other similar expressions. These statements are based on the Forte's current beliefs and expectations. Forward-looking statements include statements regarding Forte's beliefs, goals, intentions and expectations regarding its product candidate, FB102 and the therapeutic and commercial market potential of FB102, the expected timeline for the Phase 2 celiac study and related readout, and the expected timing of topline results for the FB102 vitiligo study. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: risks related to Forte's ability to obtain sufficient additional capital to continue to advance Forte's product candidate, FB102; uncertainties associated with the clinical development and regulatory approval of Forte's product candidate, FB102, including potential delays in the commencement, enrollment and completion of clinical trials; the risk that results from preclinical and the Phase 1b trials may not be predictive of future results from clinical trials; risks associated with the failure to realize any value from FB102 in light of inherent risks, expense and difficulties involved in successfully bringing product candidates to market; and additional risks, uncertainties, and other information affecting Forte's business and operating results is contained in Forte's Quarterly Report on Forms 10-Q filed on May 15, 2025, and in its other filings with the Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Source: Forte Biosciences, Inc.

Forbes

43 minutes ago

• Forbes

Opportunities And Headwinds Facing America's Emerging Public Companies

Cody Slach, Senior Managing Director at Gateway Group. While tech giants and trillion-dollar valuations dominate financial headlines, an entirely different group of companies continues to build, innovate and hustle for market share: small-cap public companies. Typically defined as businesses with market capitalizations under $2 billion, small-caps make up the backbone of American entrepreneurship on the public stage. And yet, they often remain overlooked by institutional investors, underfollowed by analysts and overburdened by regulation. Their journey is one of high potential but also high pressure. The Upside Of Being Small (And Public) Large corporations may have scale, but small-caps have speed. Without layers of bureaucracy, they can pivot faster in response to market signals. In a landscape increasingly defined by disruption, agility can be a competitive edge. Small-caps often trade at valuations that leave room for substantial upside. A successful product launch, strategic acquisition or entry into a new market can deliver meaningful growth—something harder to achieve in mature, large-cap firms. Many small-caps don't go public with dreams of becoming the next Apple—they go public to build credibility, attract capital and ultimately be acquired. For investors, that often means a built-in exit strategy with potential upside. In small-cap companies, leadership is closer to the business and often more accessible to investors. There's less institutional inertia and more incentive to perform. The Challenges Are Real—And Growing Public companies face mounting compliance costs, and for small-caps, these are felt more acutely. For example, in 2004, U.S. companies with revenues over $5 billion spent 0.06% of revenue on SOX compliance, while companies with less than $100 million in revenue spent 2.55%. With lower trading volumes and limited analyst coverage, small-cap stocks are more vulnerable to price swings. That can deter institutional capital and discourage long-term investors during market downturns. Small-cap firms often struggle to attract top-tier talent, particularly in competitive sectors like AI or biotech. Access to capital is similarly constrained, especially in tighter interest rate environments or risk-off markets. Policy Could Help—Or Hurt There's bipartisan support for revisiting regulations that disproportionately burden small public firms. Reforms could include simplified reporting for companies under a certain revenue threshold or extending the 'emerging growth company' benefits of the JOBS Act. But nothing moves quickly in Washington, and without relief, some promising firms may opt to stay private indefinitely. The Risks Can Be Justified But if investors get it right, the returns can outperform. One way to look at this is the standard deviation of daily returns—i.e., the amount prices move away from the mean. Let's take a look at that for two indices that are synonymous with small-cap and large-cap—the Russell 2000 and Russell 1000 indexes, respectively. According to LSEG, since inception, the standard deviation for the Russell 1000 was 17.54% vs. 20.01% for the Russell 2000. While those numbers may seem small, they measure a large sample size, with outliers to the upside and downside. Picking the right stock in the Russell 2000 can generate substantial alpha. While large-cap tech giants dominate headlines, small-cap public companies (again, market caps under $2 billion) play a vital yet often overlooked role in the U.S. economy. These firms offer agility, growth potential and acquisition appeal, making them attractive to investors seeking outsized returns. Their leadership is typically more accessible and accountable, and they often trade at valuations that allow for substantial upside. However, small-caps also face significant challenges: disproportionately high regulatory compliance costs, liquidity issues, limited analyst coverage, difficulty attracting talent and restricted access to capital. Policy reforms could ease some of these burdens, but progress is slow. Despite higher volatility, as shown by the Russell 2000's greater standard deviation compared to the Russell 1000, smart investors can achieve meaningful returns by picking the right small-cap stocks. Forbes Business Development Council is an invitation-only community for sales and biz dev executives. Do I qualify?

Business Wire

an hour ago

• Business Wire

Dot Ai to Begin Trading on Nasdaq Stock Market

LAS VEGAS--(BUSINESS WIRE)--SEE ID, Inc., doing business as Dot Ai (Nasdaq: DAIC) ('Dot Ai'), a pioneering startup at the forefront of asset intelligence technology, today announced that shares of its Class A common stock and warrants will commence trading on the Nasdaq Stock Market under the ticker symbols 'DAIC' and 'DAICW,' respectively, on June 23, 2025. 'We're thrilled to finalize our listing and to become a publicly traded company,' said Ed Nabrotzky, Co-founder and CEO of Dot Ai. 'Leveraging state-of-the-art artificial intelligence engines, the Internet of Things, and our patented, proprietary and innovative software, hardware and cloud integration solutions, we are revolutionizing how companies all over the world manage their supply chains, logistics operations and operational security.' 'With access to the public markets, we look forward to executing on our growth plans, delivering on our product launches, including our recently announced Zero Infrastructure Mesh and more, and ramping up operations at our Puerto Rico manufacturing hub,' Mr. Nabrotzky continued. 'Furthermore, with partners like Würth Industry USA and additional key players to be announced in the coming months, we believe Dot Ai is well positioned to capitalize on the rapidly increasing demand for modern, next-gen technology that empowers comprehensive, efficient, secure and reliable supply chains across a variety of sectors.' Key Operational Highlights In December 2024, Dot Ai unveiled ZiM (Zero Infrastructure Mesh), a next-gen Internet of Things (IoT) tracking technology, to replace the outdated and expensive technologies that logistics operations have relied on for decades. ZiM is designed to offer an innovative asset management solution by securely gathering data at the edge of the enterprise. It can read both passive (battery free transponders) and active (battery powered beacons) to provide data for supervisory systems. The bridge can operate with its own battery power when mounted on moving racks or pallets or be hardwired to power for fixed installation in aisles or doorways. Puerto Rico Facility In May 2025, in partnership with Invest Puerto Rico ('Invest PR'), the island's business attraction organization, Dot Ai announced plans to establish its first hardware manufacturing operation in Barceloneta. The company chose Puerto Rico to benefit from U.S. jurisdictional protections, strong intellectual property enforcement and access to global markets from a domestic base. Dot Ai projects the facility will result in the creation of up to 200 full-time jobs over the next five years, subject to business conditions and operational scaling. Dot AI's new facility in Barceloneta will manufacture and globally distribute its patented IoT tracking systems, boosting Puerto Rico's reputation as a hub for cutting-edge technology and advanced manufacturing. Partnership with Wurth Industry USA In November 2024, Dot Ai and Würth Industry USA ('Würth'), a leading industrial distributor and division of the Würth Group, announced the execution of a five-year agreement to bring Dot Ai's advanced, AI-driven tracking solutions to Würth's customers. This access offers Würth unprecedented visibility into internal and customer premise operations and provides Dot Ai an exclusive partnership to serve Würth's manufacturing vertical. Under this agreement, Würth customers gain access to Dot Ai's state-of-the-art track and trace technology, including the ZiM Bridge, Industrial Passive asset tag solution (which requires no battery), and a cloud-based, AI platform that continually optimizes processes. These innovations are being seamlessly integrated with Würth's customized CPS ® kanban inventory management solutions, providing real-time data and increasing responsiveness to changing demands, resulting in unprecedented supply chain metrics and security. About Dot Ai At the heart of the technological revolution in asset management and security lies Dot Ai, a trailblazing SaaS service that is redefining the paradigms of asset intelligence, assurance and safety. By harnessing the power of IoT tracking technology, Dot Ai stands at the forefront of innovation, offering patented solutions that are not just advanced but transformative. Through relentless research and development, Dot Ai has pioneered a suite of technologies that empower organizations to not only streamline their logistics and supply chain processes but also bolster operational security to unprecedented levels. Leveraging state-of-the-art AI engines, cutting-edge 5G RF and BLE technology, and seamless cloud integrations, Dot Ai transcends traditional boundaries, offering real-time asset visibility and predictive analytics that integrate effortlessly with existing infrastructure. This is not just technology; it's a vision for a more secure, efficient, and connected world. Discover more about how Dot Ai is leading the charge in asset intelligence by visiting Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts, including the statements regarding the anticipated timing to commence trading on the Nasdaq Stock Market, plans regarding the execution of its growth plans, expectations regarding its ZiM product launch and its Puerto Rico Facility expansion. All forward-looking statements are based on ShoulderUp's current expectations and beliefs concerning future developments and their potential effects on ShoulderUp, SEE ID or any successor entity thereof. Forward-looking statements are based on various assumptions, whether or not identified in this press release, and are subject to risks and uncertainties. These forward-looking statements are not intended to serve as a guarantee of future performance. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) risks that the transaction and listing disrupt current plans and operations of SEE ID, (ii) costs related to the transaction and the failure to realize anticipated benefits of the transaction or to realize estimated pro forma results and underlying assumptions, (iii) the risk that SEE ID and its current and future collaborators are unable to successfully develop and commercialize SEE ID's products or services, or experience significant delays in doing so, (iv) the risk that SEE ID may need to raise additional capital to execute its business plan, which many not be available on acceptable terms or at all, (v) the risk that the post-combination company experiences difficulties in managing its growth and expanding operations. The foregoing list of factors is not exhaustive; (vi) competition, the ability of SEE ID to grow and manage growth profitably, and retain its management and key employees; (vii) changes in applicable laws or regulations; and (viii) weakness in the economy, market trends, uncertainty and other conditions in the markets in which SEE ID operates, and other factors beyond its control, such as inflation or rising interest rates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of the S-4 Registration Statement and proxy statement/prospectus discussed above and other documents filed or to be filed by ShoulderUp, SEE ID and/or any successor entity thereof from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ShoulderUp assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.